ArticleJournal of natural products2011
Cyclic depsipeptides, grassypeptolides D and E and Ibu-epidemethoxylyngbyastatin 3, from a Red Sea Leptolyngbya cyanobacterium.
Article in Journal of natural products, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 73 citations in OpenAlex.
- Chemical diversity of cyanobacterial natural products.Natural product reports · 2025Review
- Leptochelins A-C, Cytotoxic Metallophores Produced by Geographically DispersedJournal of the American Chemical Society · 2024Article
- A Review of the Antimicrobial Properties of Cyanobacterial Natural Products.Molecules (Basel, Switzerland) · 2023Review
- Marine Cyanobacterial Peptides in Neuroblastoma: Search for Better Therapeutic Options.Cancers · 2023Review
- Marine Organisms as a Prolific Source of Bioactive Depsipeptides.Marine drugs · 2023Review
- Biosynthesis of Lyngbyastatins 1 and 3, Cytotoxic Depsipeptides from anJournal of natural products · 2023Article
- Emerging Trends of Nanotechnology and Genetic Engineering in Cyanobacteria to Optimize Production for Future Applications.Life (Basel, Switzerland) · 2022Review
- Therapeutic potential of marine peptides in cervical and ovarian cancers.Molecular and cellular biochemistry · 2022Review
- The intriguing chemistry and biology of sulfur-containing natural products from marine microorganisms (1987-2020).Marine life science & technology · 2021Review
- Phormidepistatin from the Cyanobacterium UIC 10484: Assessing the Phylogenetic Distribution of the Statine Pharmacophore.Journal of natural products · 2021Article
- Natural Cyclopeptides as Anticancer Agents in the Last 20 Years.International journal of molecular sciences · 2021Review
- Cyanobacteria as Natural Therapeutics and Pharmaceutical Potential: Role in Antitumor Activity and as Nanovectors.Molecules (Basel, Switzerland) · 2021Review
- Bioactive Compounds from Marine Heterobranchs.Marine drugs · 2020Review
- The Chemistry, Biochemistry and Pharmacology of Marine Natural Products fromMarine drugs · 2020Review
- Natural Products Repertoire of the Red Sea.Marine drugs · 2020Review
- Bioactive compounds from marine invertebrates as potent anticancer drugs: the possible pharmacophores modulating cell death pathways.Molecular biology reports · 2020Review
- Natural Bioactive Thiazole-Based Peptides from Marine Resources: Structural and Pharmacological Aspects.Marine drugs · 2020Review
- Article
- Jizanpeptins, Cyanobacterial Protease Inhibitors from a Symploca sp. Cyanobacterium Collected in the Red Sea.Journal of natural products · 2018Article
- Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Two new grassypeptolides and a lyngbyastatin analogue, together with the known dolastatin 12, have been isolated from field collections and laboratory cultures of the marine cyanobacterium Leptolyngbya sp. collected from the SS Thistlegorm shipwreck in the Red Sea. The overall stereostructures of grassypeptolides D (1) and E (2) and Ibu-epidemethoxylyngbyastatin 3 (3) were determined by a combination of 1D and 2D NMR experiments, MS analysis, Marfey's methodology, and HPLC-MS. Compounds 1 and 2 contain 2-methyl-3-aminobutyric acid and 2-aminobutyric acid, while biosynthetically distinct 3 contains 3-amino-2-methylhexanoic acid and the β-keto amino acid 4-amino-2,2-dimethyl-3-oxopentanoic acid (Ibu). Grassypeptolides D (1) and E (2) showed significant cytotoxicity to HeLa (IC₅₀ = 335 and 192 nM, respectively) and mouse neuro-2a blastoma cells (IC₅₀ = 599 and 407 nM, respectively), in contrast to Ibu-epidemethoxylyngbyastatin 3 (neuro-2a cells, IC₅₀ > 10 μM) and dolastatin 12 (neuro-2a cells, IC₅₀ > 1 μM).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.